Browsing by Subject Risk Assessment
Showing results 1 to 7 of 7
| Publication Date | Title | Author(s) |
|---|---|---|
| 1-Mar-2021 | A living WHO guideline on drugs to prevent covid-19 | Lamontagne F; Agoritsas T; Siemieniuk R; Rochwerg B; Bartoszko J; Askie L; Macdonald H; Amin W; Bausch FJ; Burhan E; Cecconi M; Chanda D; Dat VQ; Du B; Geduld H; Gee P; Nerina H; Hashimi M; Hunt BJ; Kabra S; Kanda S; Kawano-Dourado L; Kim Y-J; Kissoon N; Kwizera A; Leo Y-S; Mahaka I; Manai H; Mino G; Nsutebu E; Pshenichnaya N; Qadir N; Ranganathan SS; Sabzwari S; Sarin R; Sharland M; Shen Y; Souza JP; Stegemann M; Ugarte S; Venkatapuram S; Vuyiseka D; Preller J; Brignardello-Petersen R; Kum E; Qasim A; Zeraatkar D; Owen A; Guyatt G; Lytvyn L; Diaz J; Vandvik PO; Jacobs M |
| Apr-2012 | COMPARING THE RISK OF THE PRESSURE TUBE-SCWR TO THE CANDU USING PROBABILISTIC RISK ASSESSMENT TOOLS | ITUEN, IMA |
| 6-Jul-2020 | Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis | Devasenapathy N; Ye Z; Loeb M; Fang F; Najafabadi BT; Xiao Y; Couban R; Bégin P; Guyatt G |
| Aug-2020 | Hidden in plain sight: Addressing the unique needs of high‐risk psychiatric populations during the COVID ‐19 pandemic | Hategan A; Abdurrahman M |
| Nov-2014 | Modeling and Assessment of Emergency Mitigation Preparedness & Vulnerability for External Events in Nuclear Power Plants | Assi, Ahmad |
| Apr-2021 | Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond | Beecker J; Papp KA; Dutz J; Vender RB; Gniadecki R; Cooper C; Gisondi P; Gooderham M; Hong CH; Kirchhof MG; Lynde CW; Maari C; Poulin Y; Puig L |
| 1997 | Screening for hypercholesterolemia in primary care practice | Hutchison, Brian G.; Centre for Health Economics and Policy Analysis |
